Pain occurs frequently in patients with cancer; when poorly controlled, it may significantly interfere with their daily activities and negatively impact their quality of life ([@b1-prm-20-249],[@b2-prm-20-249]). A meta-analysis reported varying pooled prevalence rates of pain in the cancer trajectory: 33% (95% CI 21% to 46%) following curative treatment; 59% (95% CI 44% to 73%) in those receiving anticancer treatment; 64% (95% CI 58% to 69%) in those with advanced, metastatic or terminal disease; and 53% (95% CI 43% to 63%) for all disease stages ([@b3-prm-20-249]). More recent meta-analyses, one investigating chemotherapy-induced peripheral neuropathy ([@b4-prm-20-249]), and another investigating older cancer patients receiving palliative care ([@b5-prm-20-249]), reported prevalence rates of 68.1% (95% CI 57.7% to 78.4%) and 66.3% (95% CI 35.8% to 83.9%), respectively. A survey of 5804 patients with all stages of cancer in 11 European countries (excluding Portugal) and Israel reported that 56% suffered moderate to severe pain monthly ([@b6-prm-20-249]). There are few literature data on cancer pain (CP) characteristics in the Portuguese population. A cross-sectional survey of 164 patients, 151 (92%) with cancer, reported that pain was assessed in 136 (83%) and of these, 77 (57%) had pain at the time of assessment ([@b7-prm-20-249]).

Despite the high prevalence of pain in the cancer trajectory, a multicentre Italian study of 1801 patients ([@b8-prm-20-249]), a vignette-related survey involving 2000 oncologists in the United States with a 32% response rate ([@b9-prm-20-249]), a systematic review of CP in nursing home residents ([@b10-prm-20-249]) and a pooled review of 44 CP management studies ([@b11-prm-20-249]) collectively suggest that CP is, overall, inadequately treated. Although opioids are the mainstay of CP management according to guidelines from the WHO ([@b12-prm-20-249]), the European Society for Medical Oncology ([@b13-prm-20-249]) and the European Association for Palliative Care ([@b14-prm-20-249]), they are underused, especially in elderly patients ([@b15-prm-20-249],[@b16-prm-20-249]). Underuse is due to a mix of patient, physician, and health system and cultural factors ([@b9-prm-20-249],[@b17-prm-20-249],[@b18-prm-20-249]), including 'morphinophobia', as determined in a regional Portuguese study ([@b19-prm-20-249]).

One of the most consistent reasons identified for poor CP management is inadequate assessment and classification of pain ([@b9-prm-20-249],[@b20-prm-20-249],[@b21-prm-20-249]). CP is multidimensional in nature, varying in physical, psychosocial and spiritual components. The patient's expression of pain, reported as pain intensity, is therefore complex ([@b22-prm-20-249]). Younger age, neuropathic features, incident pain, psychological distress and addiction history have each been identified as predictors of longer time to achieve stable analgesia ([@b23-prm-20-249],[@b24-prm-20-249]). Pain intensity has been identified in some but not all studies as a predictor of the time required to achieve stable pain control ([@b22-prm-20-249],[@b23-prm-20-249],[@b25-prm-20-249]).

Given projected global demographic changes ([@b26-prm-20-249]), and the associated increase in the number of patients with cancer ([@b27-prm-20-249]), there is a compelling need to better understand the nature of CP and inform evidence-based strategies for its assessment, classification and management. The present study aimed to describe the characteristics of CP and determine the correlates and predictors of initial pain intensity (iPI) when patients were referred to a CP clinic in Portugal.

METHODS
=======

Setting and design
------------------

The present study was conducted from June 1, 2009 to April 30, 2010 in the specialist CP clinic of the Portuguese Cancer Institute, a national tertiary-level cancer centre in Lisbon, Portugal. The study was cross-sectional in design, reflecting assessments that were conducted at subjects' first consultation in the CP clinic.

Study population and eligibility criteria
-----------------------------------------

Consecutive new patient referrals to an outpatient CP clinic were approached for consent to participate in both an initial cross-sectional and a related longitudinal study of CP characteristics and management. The following eligibility criteria were applied: adult patients (\>18 years of age) were included if they had a cancer diagnosis, provided informed consent to study participation, and had the cognitive capacity to rate their current pain on a numerical rating scale (0 meaning no pain, 10 meaning the worst pain imaginable); patients were excluded if they had no evidence of active cancer or had non-cancer-related pain. CP was defined as pain directly related to malignant involvement or pain related to anticancer treatment, such as chemotherapy, radiotherapy or surgery. Ethics approval for the present study was obtained from the Research Ethics Board of the Portuguese Cancer Institute. The assembling of an electronic study dataset with numerical identifiers was approved by the Portuguese Data Protection Authority.

Assessment data and tools
-------------------------

Patients underwent standardized assessments and documentation of clinical data. Translated Portuguese versions of standard tools that were previously validated in English and also, in most cases, in Portuguese, were used. For ease of reporting, the Portuguese socioeconomic groupings of 1, 2 and 3; 4, 5 and 6; 7 and 8; and 9 were transformed in a similar descending order to groups 1, 2, 3 and 4, respectively ([@b28-prm-20-249]). Regarding education, primary referred to zero to four years of education; secondary referred to five to 12 years; and tertiary referred to university or \>12 years. A history of chronic depression referred to depression preceding the cancer diagnosis and requiring ongoing antidepressant medication. In addition to a global clinical rating of functional dependency level (independent, partial or fully dependent), functional status (0 to 4: 0, fully active and able to carry on all predisease performance without restriction; 4, indicating that the patient is unable to provide self-care and confined to bed or chair) was rated using the Eastern Cooperative Oncology Group (ECOG) scale ([@b29-prm-20-249]). Scores of ≥2 on the CAGE alcohol questionnaire ([@b30-prm-20-249],[@b31-prm-20-249]), ≥4 on a Portuguese-translated version (unpublished) of the original Short Portable Mental Status Questionnaire ([@b32-prm-20-249]), \>7 on the anxiety and depression subscales of the Hospital Anxiety and Depression Scale (HADS) ([@b33-prm-20-249]) and ≥4 on the Emotion Thermometer (ET) tool ([@b34-prm-20-249],[@b35-prm-20-249]) were used to screen for a history of alcohol abuse, cognitive impairment, anxiety, depression, and emotional distress, respectively.

Documentation of palliative status (in relation to the goals of treatment) was recorded when present. Cancer disease-modifying treatments (cytotoxic chemotherapy, radiotherapy or surgery) ≤30 days before first CP clinic consultation were recorded. Pain data included the Brief Pain Inventory (BPI) pain intensity ratings (worst and average in the past seven days) ([@b36-prm-20-249],[@b37-prm-20-249]) 'pain now,' as the primary outcome variable, labelled as iPI, on a 0 to 10 scale; and pain duration. CP pain mechanism was classified according to both standard clinical assessment and a DN4 score of ≥4 to designate a neuropathic CP component ([@b37-prm-20-249],[@b38-prm-20-249]); other categories were visceral, bone and mixed. Episodic pain, defined as a transitory exacerbation of pain that occurs in addition to otherwise stable persistent pain ([@b39-prm-20-249]), was recorded and subdivided into episodic incident pain when a trigger or incident activity was identifiable and episodic breakthrough pain when no trigger was identified. The oral morphine equivalent daily dose (MEDD) was calculated according to standard recommendations ([@b40-prm-20-249]), and recorded along with the number of current adjuvant (pharmacological) analgesic treatments (grouped as none, and one or more).

Data analyses
-------------

SAS statistical software version 9.1 (SAS Institute Inc, USA) was used for data analysis. Means are expressed with SDs, and medians are expressed with the first to third quartile range (Q1 to Q3) unless otherwise stated. The initial MEDD was highly skewed and underwent logarithmic transformation for further analysis. With iPI as outcome, univariable analyses were conducted using the *t* test, one-way ANOVA and Pearson correlation (r), as appropriate for independent categorical and continuous variables, respectively. Variables with P\<0.1 were entered into a multivariable regression model, using backward elimination and a cut-point of P=0.2 for final model selection. The coefficient of determination (R^2^) for the model was calculated and adjusted. Statistical significance was set at P\<0.05 for analyses.

RESULTS
=======

Of 459 individual patient referrals to the CP clinic, 88 were excluded because of non-cancer-related pain (n=69), nonactive cancer (n=16) or failure to consent (n=3). Demographic, psychosocial and functional status data and corresponding iPI ratings are summarized in [Table 1](#t1-prm-20-249){ref-type="table"}. In the final study sample (n=371), the mean age was 62.1±14.3 years; 199 (54%) were female. A mild cognitive deficit was detected in 46 (12.4%) of patients. Approximately one-half of the study sample were classed as partially or fully dependent, and 62 (16.7%) had ECOG scores of 3 or 4.

Cancer disease and pain characteristics with corresponding iPI ratings are summarized in [Table 2](#t2-prm-20-249){ref-type="table"}. Of 371 patients, 263 (71%) had meta-static disease, and 176 (47%) had their treatment goal documented as palliative. The majority of cancers were solid tumours and 18 (4.8%) hematological malignancies accounted for the remainder. Lung cancer accounted for 10 (2.7%) of the cancer diagnoses.

Most pain syndromes (246 \[66%\]) were mixed neuropathic and nociceptive. Using pain intensity scores derived from the BPI, the mean iPI (pain now), pain worst and pain average were mean (± SD) scores of 5.4±2.6, 7.4±2.6 and 4.9±1.9, respectively, and all were highly correlated (r\>0.8, P\<0.0001). Categorizing iPI scores into conventional verbal pain intensity ratings, 86 (23.2%), 152 (41%) and 133 (35.8%) of patients had mild (0 to 3), moderate (4 to 6) and severe (7 to 10) pain, respectively. The median (Q1 to Q3) pain duration was three (two to six) months. The initial median MEDD was 30 mg (20 mg to 60 mg). Forty-two patients had a mean iPI of 2.55±2.33 and were not receiving any opioid.

In the univariable analyses testing the association of iPI with categorical variables ([Tables 1](#t1-prm-20-249){ref-type="table"} and [2](#t2-prm-20-249){ref-type="table"}), a positive association was found in relation to higher income and upper socioeconomic groups (groups 1, 2 and 3); a history of drug or alcohol abuse; greater functional dependency; 'palliative' status designation; primary cancer diagnosis (the highest iPI groups were those with head and neck, gastrointestinal, and genitourinary cancer); recent radiotherapy treatment; the presence of neuropathic CP or mixed pain; presence of metastases; and use of ≥1 adjuvant analgesic medication (P\<0.05)

In the univariable analyses testing the association of iPI with continuous variables ([Table 3](#t3-prm-20-249){ref-type="table"}), the only significant association occurred in relation to the initial MEDD (P\<0.05), which was positive in direction. The HADS depression and anxiety subscale scores were \>10 in 239 (64.4%) and 215 (57.9%) of patients, respectively, indicating abnormal levels of depression and anxiety. The ET scores were ≥4 for distress, anxiety, depression, anger and help desired in 208 (56%), 271 (73%), 280 (75.5%), 216 (58.2%) and 209 (56.3%), respectively.

In the multivariable model ([Table 4](#t4-prm-20-249){ref-type="table"}), nine variables were retained and five were positively associated with iPI: higher income, ECOG ratings 3 to 4, cancer type (head and neck, genitourinary and gastrointestinal); adjuvant use and initial MEDD (P\<0.05). The adjusted R^2^ for this model was 18.6; thus, the model explained \<20% of the variance in iPI.

DISCUSSION
==========

Using iPI ratings recorded as 'pain now' at the first CP clinic consultation, our study showed a high correlation between this measure and those of 'pain worst' and 'pain average' over the preceding seven days, suggesting that 'pain now' has validity as a measure of patients' overall experience of pain intensity in the week preceding their initial CP clinic consultation. Our study sample was comparatively unique in that it included patients with earlier stage cancer, in addition to 47% whose treatment goals were documented as palliative. However, we have no data to verify the consistency and accuracy of this latter designation, other than indirectly inferred evidence, given that 71% had metastatic disease. Compared with other studies of pain in predominantly inpatient palliative care or hospice based populations ([@b7-prm-20-249],[@b24-prm-20-249],[@b37-prm-20-249]), our outpatient sample had a relatively high performance status; only 16.7% had ECOG scores of 3 or 4. Furthermore, because longitudinal studies of pain intensity may generate more robust data regarding its predictors, correlates and variability ([@b15-prm-20-249],[@b38-prm-20-249]), this needs to be acknowledged when comparing our study findings with those of longitudinal studies ([@b23-prm-20-249],[@b25-prm-20-249]).

There is substantial evidence of suboptimal CP management by medical oncologists in the United States ([@b9-prm-20-249]). The situation in Portugal is probably no different: although 77% of our study sample had pain of either moderate or severe intensity, based on their iPI ratings, the initial median (Q1 to Q3) MEDD of our sample was 30 mg (20 mg to 60 mg), which is very low compared with other studies ([@b41-prm-20-249],[@b42-prm-20-249]), and suggestive of opioid underuse. It supports the finding of a population-based survey of patients with chronic pain in Portugal, in which the reported prevalence rate of opioid use in those with chronic CP was 10.13% ([@b43-prm-20-249]). This warrants further standardized evaluation using a tool such as the Pain Management Index ([@b44-prm-20-249]).

Despite literature data supporting the association of psychosocial distress with pain intensity levels ([@b23-prm-20-249],[@b24-prm-20-249],[@b41-prm-20-249]), and despite our sample's HADS and ET scores reflecting a very high level of such distress, we surprisingly found no dimensional correlation between these and iPI. Recognizing that all of the patients in our sample had some level of CP, it is possible that an association between CP and psychological distress might be more readily detected on a categorical rather than a dimensional severity basis, if we had conducted a broader population study to determine psychological distress in relation to the categorical presence or absence of CP. Regarding assessment tools, we used versions of the BPI and HADS that were validated in Portuguese, as spoken in Portugal ([@b33-prm-20-249],[@b37-prm-20-249]). We used versions of the CAGE and ET that were validated in Brazilian Portuguese ([@b31-prm-20-249],[@b35-prm-20-249]) and, thus, we cannot exclude the possible contribution of interpretive error to the lack of correlation between ET scores and iPI. Other researchers have demonstrated the association between CP and psychological distress ([@b23-prm-20-249],[@b24-prm-20-249],[@b41-prm-20-249]), and although there is some commonality in the biological pathways that subserve depression and pain ([@b45-prm-20-249]), studies have not been designed to determine a causal relationship in either direction ([@b46-prm-20-249]). An association between CP intensity and a history of drug or alcohol abuse has been demonstrated in some studies ([@b23-prm-20-249],[@b24-prm-20-249]). Although a drug or alcohol abuse history had a statistically significant association with iPI in our univariable analysis, an independent association was not evident in the multivariable analysis. Other studies have demonstrated an association between pain intensity and episodic incident pain ([@b22-prm-20-249],[@b23-prm-20-249],[@b42-prm-20-249]); however, our study failed to demonstrate this. Although our cross-sectional study found that psychosocial distress, a history of drug or alcohol abuse, and episodic pain were not independently associated with initial pain intensity, a longitudinal analysis may be more sensitive in detecting such associations.

In our final multivariable model, the primary cancer diagnoses of head and neck, genitourinary and gastrointestinal were independent predictors of higher iPI. The relatively high prevalence (29.2%) of neuropathic pain in the head and neck group may explain their higher iPI. Among the demographic variables, both higher income and poorer performance status were independently associated with iPI. We can only surmise that those on lower incomes may be less well able to verbalise their iPI. Our finding that iPI was associated with poorer performance status is consistent with literature data ([@b47-prm-20-249]). Unlike other studies ([@b23-prm-20-249],[@b24-prm-20-249]), age was not associated with iPI in our current study. Adjuvant use was independently associated with iPi, possibly reflecting an evidence-based approach to neuropathic pain management. The strongest independent association with iPI occurred in relation to opioid dose at the point of referral, reflecting an approach that is generally consistent with current guidelines, albeit possibly inadequate in terms of actual opioid dosing.

Our study has some unique features: its knowledge synthesis contribution is significant, given the limited literature data regarding CP in a Portuguese setting; its approach involved a comprehensive combination of standardized assessments with validated tools. Our study also has significant limitations. First, the presence of a referral bias is very likely with a CP clinic, as reflected by 77% of patients having moderate or severe pain. The number of patients with lung cancer was relatively low at 10%, whereas the number with head and neck cancer was relatively high at 24.8%. Second, the cross-sectional design of our study only captures a narrow temporal window of patients' pain intensity experience. This justifies conducting a longitudinal study to obtain more robust data. Third, the R^2^ of the final multivariable model was 18.6, indicating that it only explained approximately 19% of the variance in pain intensity, a finding that may reflect the known and unknown dimensions of pain intensity and further substantiates the need for a longitudinal study.

CONCLUSION
==========

Pain intensity is associated with a heterogenous group of factors: higher income; poorer functional performance status; cancer type (head and neck, genitourinary and gastrointestinal); adjuvant use and initial opioid dose. The diversity of associations, and our study's limited explanation of pain intensity variance (\<20%), together underscore the biopsychosocial complexity of CP. The level of opioid dosing was likely suboptimal in patients referred to our CP clinic. Adequacy of CP treatment therefore warrants further exploration. Prospective longitudinal studies are particularly needed to better understand CP, such as the contribution of neuropathic and other challenging components, and thus inform its classification and management.
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###### 

Demographic, psychosocial and functional status variables and their associations with initial pain intensity (n=371)

  **Variable**                    **n (%)**    **Initial pain intensity**   **P**              
  ------------------------------- ------------ ---------------------------- ------- ---------- -------
  **Demographics**                                                                             
  Sex                                                                                          
    Male                          172 (46.4)   5.43±2.39                    6       4--7       0.715
    Female                        199 (53.6)   5.33±2.81                    6       3--7       
  Age, years                                                                                   
    \<60                          146 (39.4)   5.23±2.77                    6       3--7       0.371
    ≥60                           225 (60.6)   5.48±2.52                    6       4--7       
  Education                                                                                    
    Primary level                 259 (69.8)   5.47±2.60                    6       4--7       0.316
    Secondary or tertiary         112 (30.2)   5.17±2.67                    6       3--7       
  Work status                                                                                  
    Active                        47 (12.7)    5.11±2.79                    6       2--7       0.884
    Disability leave              57 (15.4)    5.35±2.53                    6       4--7       
    Retired                       243 (65.5)   5.44±2.61                    6       4--7       
    Unemployed                    24 (6.5)     5.33±2.68                    6       3.5--7.5   
  Socioeconomic group                                                                          
    1, 2, 3                       282 (76.0)   5.56±2.50                    6       4--7       0.019
    4                             89 (24.0)    4.81±2.91                    5       2--7       
  Income                                                                                       
    ≤€485/month                   176 (47.4)   5.06±2.71                    6       3--7       0.025
    \>€485/month                  195 (52.6)   5.67±2.51                    6       4--7       
  **Clinical history**                                                                         
  Chronic depression                                                                           
    No                            349 (94.0)   5.37±2.61                    6       4--7       0.76
    Yes                           22 (6.0)     5.55±2.77                    6       3--8       
  Alcohol abuse history                                                                        
    No                            288 (77.6)   5.19±2.67                    6       3--7       0.012
    Yes                           83 (22.4)    6.01±2.34                    6       5--8       
  Drug or alcohol abuse history                                                                
    No                            285 (76.8)   5.22±2.67                    6       3--7       0.032
    Yes                           86 (23.2)    5.91±2.40                    6       5--7       
  Tobacco smoking                                                                              
    Never                         268 (72.2)   5.45±2.67                    6       4--7       0.699
    Ex-smoker                     30 (8.1)     5.13±2.43                    6       4--6       
    Current                       73 (19.7)    5.22±2.53                    6                  
  **Functional status**                                                                        
  Cognitive status                                                                             
    Normal                        325 (87.6)   5.30±2.64                    6       4--7       0.123
    Mild deficit                  46 (12.4)    5.93±2.43                    6       4--7       
  Functional dependency                                                                        
    Independent                   192 (51.7)   5.01±2.74                    6       3--7       0.005
    Dependent                     179 (48.3)   5.77±2.43                    6       5--7       
    ECOG                                                                                       
      0, 1, 2                     309 (83.3)   5.21±2.66                    6       3--7       0.007
      3, 4                        62 (16.7)    6.19±2.28                    6.5     5--8       

ECOG Eastern Cooperative Oncology Group

###### 

Cancer disease and pain characteristics, and their association with initial pain intensity (n=371)

  **Variable**                              **n (%)**    **Initial pain intensity (iPI)**   **P**            
  ----------------------------------------- ------------ ---------------------------------- ------- -------- ----------
  **Cancer characteristics**                                                                                 
  Cancer diagnosis                                                                                           
    Head and neck                           92 (24.8)    5.73±2.22                          6       5--7     0.008
    Lung                                    10 (2.7)     5.20±2.25                          4.5     4--7     
    Gastrointestinal                        82 (22.1)    5.62±2.69                          6       4--7     
    Breast                                  43 (11.6)    5.30±3.07                          6       2--8     
    Genitourinary                           79 (21.3)    5.70±2.31                          6       5--7     
    Other                                   65 (17.5)    4.26±2.91                          4       2--7     
  Metastatic disease                                                                                         
    No                                      108 (29.1)   4.74±2.84                          5       2--7     0.003
    Yes                                     263 (70.9)   5.64±2.48                          6       4--7     
  Bone metastases                                                                                            
    No                                      242 (65.2)   5.19±2.69                          6       3--7     0.059
    Yes                                     129 (34.8)   5.73±2.46                          6       4--7     
  Palliative treatment goal                                                                                  
    No                                      195 (52.6)   4.87±2.83                          6       2--7     \<0.0001
    Yes                                     176 (47.4)   5.94±2.24                          6       5--7     
  Surgery                                                                                                    
    No                                      259 (69.8)   5.39±2.68                          6       4--7     0.922
    Yes                                     112 (30.2)   5.36±2.49                          6       4--7     
  Chemotherapy                                                                                               
    No                                      204 (55.0)   5.21±2.78                          6       3--7     0.176
    Yes                                     167 (45.0)   5.58±2.41                          6       4--7     
  Radiotherapy                                                                                               
    No                                      195 (52.6)   5.11±2.92                          6       2--7     0.038
    Yes                                     176 (47.4)   5.67±2.22                          6       4.5--7   
  **Cancer pain characteristics**                                                                            
  Nociceptive visceral                                                                                       
    No                                      259 (69.8)   5.29±2.64                          6       4--7     0.349
    Yes                                     112 (30.2)   5.57±2.58                          6       4--7     
  Nociceptive soft tissue                                                                                    
    No                                      153 (41.2)   5.52±2.47                          6       3--7     0.216
    Yes                                     218 (58.8)   5.57±2.58                          6       4--7     
  Nociceptive bone pain                                                                                      
    No                                      222 (59.8)   5.18±2.67                          6       3--7     0.070
    Yes                                     149 (40.2)   5.68±2.52                          6       4--7     
  NeuP (DN4-positive)                                                                                        
    No                                      210 (56.6)   4.73±2.82                          5       2--7     \<0.0001
    Yes                                     161 (43.4)   6.22±2.05                          6       5--8     
  NeuP (DN4-positive) or clinically mixed                                                                    
    No                                      84 (22.6)    4.63±2.83                          6       2--7     0.003
    Yes                                     287 (77.4)   5.60±2.52                          6       4--7     
  Episodic incident                                                                                          
    No                                      151 (40.7)   5.43±2.65                          6       4--7     0.747
    Yes                                     220 (59.3)   5.34±2.60                          6       4--7     
  Episodic breakthrough                                                                                      
    No                                      212 (57.1)   5.17±2.77                          6       3--7     0.066
    Yes                                     159 (42.9)   5.66±2.38                          6       4--7     
  Adjuvant analgesics                                                                                        
    None                                    161 (43.4)   4.87±2.79                          6       2--7     0.001
    ≥ 1                                     210 (56.6)   5.77±2.42                          6       4--7     

NeuP Neuropathic pain

###### 

Correlation of psychosocial screening scores and pain characteristics with initial pain intensity

  **Variable**                                                                        **Correlation (r)**   **P**
  ----------------------------------------------------------------------------------- --------------------- ----------
  HADS anxiety score                                                                  0.04                  0.4
  HADS depression score                                                               0.06                  0.3
  Emotional thermometer scores                                                                              
  Distress                                                                            0.00                  0.9
  Anxiety                                                                             0.06                  0.3
  Depression                                                                          0.04                  0.5
  Anger                                                                               −0.00                 0.9
  Help desired                                                                        0.08                  0.1
  Duration of pain, months                                                            0.04                  0.4
  Initial morphine equivalent daily dose[\*](#tfn3-prm-20-249){ref-type="table-fn"}   0.32                  \<0.0001

Log value. HADS Hospital Anxiety and Depression Scale

###### 

Multivariable model to determine independent associations with initial pain intensity[\*](#tfn4-prm-20-249){ref-type="table-fn"}

  **Parameter**                                                                        **Estimate**   **Pr \> t \|**
  ------------------------------------------------------------------------------------ -------------- ----------------
  Intercept                                                                            1.775          0.0009
  Income \>€485/month                                                                  0.596          0.02
  Socioeconomic groups 1,2,3                                                           0.483          0.10
  Eastern Cooperative Oncology Group: 3,4                                              0.782          0.03
  Palliative status documented: Yes                                                    0.47           0.10
  Cancer diagnosis: head and neck                                                      0.867          0.03
  Cancer diagnosis: lung                                                               −0.087         0.92
  Cancer diagnosis: gastrointestinal                                                   1.054          0.01
  Cancer diagnosis: breast                                                             0.448          0.36
  Cancer diagnosis: genitourinary                                                      0.994          0.01
  Neuropathic pain (DN4-positive) or clinically classed as mixed                       0.506          0.11
  Adjuvant use: one or more                                                            0.591          0.02
  Bone metastases: yes                                                                 0.385          0.18
  Initial morphine equivalent daily dose^[†](#tfn5-prm-20-249){ref-type="table-fn"}^   0.426          \<.0001

*Adjusted R^2^* *of model = 18.6;*

Log value
